Search

Your search keyword '"Tanner, Caroline M."' showing total 112 results

Search Constraints

Start Over You searched for: Author "Tanner, Caroline M." Remove constraint Author: "Tanner, Caroline M." Database eScholarship Remove constraint Database: eScholarship
112 results on '"Tanner, Caroline M."'

Search Results

1. Occupational Pesticide Exposure in Parkinson’s Disease Related to GBA and LRRK2 Variants

2. Impact of the Dopamine System on Long‐Term Cognitive Impairment in Parkinson Disease: An Exploratory Study

Catalog

Books, media, physical & digital resources

3. The Impact of the COVID‐19 Pandemic on Care Partners of People with Parkinson's Disease

4. Impact of possible tardive dyskinesia on physical wellness and social functioning: results from the real-world RE-KINECT study

5. Trichloroethylene: An Invisible Cause of Parkinson’s Disease?

6. Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice

7. Study in Parkinson’s disease of exercise phase 3 (SPARX3): study protocol for a randomized controlled trial

8. Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia

9. Predicting Parkinson’s Disease and Its Pathology via Simple Clinical Variables

10. Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease

11. Recruitment for Remote Decentralized Studies in Parkinson’s Disease

12. Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease

13. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease

14. Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson's Disease.

15. Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia

16. Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.

17. Current Knowledge on the Evolution of Care Partner Burden, Needs, and Coping in Parkinson's Disease

18. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism.

19. Video-based Parkinson’s disease assessments in a nationwide cohort of Fox Insight participants

20. Video-based Parkinson's disease assessments in a nationwide cohort of Fox Insight participants.

21. The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism

22. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression

23. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson's Disease Progression.

24. Nonsteroidal Anti-inflammatory Use and LRRK2 Parkinson's Disease Penetrance.

25. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease

26. Evolution of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease.

27. Current and projected future economic burden of Parkinson’s disease in the U.S.

28. Electrocardiographic changes predate Parkinson's disease onset.

29. Remote telemedicine evaluation of deep brain stimulation candidacy: Retrospective cohort analysis.

30. RE-KINECT

31. Clinical and Dopamine Transporter Imaging Characteristics of Leucine Rich Repeat Kinase 2 (LRRK2) and Glucosylceramidase Beta (GBA) Parkinson's Disease Participants in the Parkinson's Progression Markers Initiative: A Cross-Sectional Study.

32. Cervical dystonia incidence and diagnostic delay in a multiethnic population.

33. Cervical dystonia incidence and diagnostic delay in a multiethnic population.

34. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology

35. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease

36. Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson’s Disease Research: The Fox Insight Cohort Experience

37. The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease

38. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.

39. Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)

40. Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP).

41. The Effect of the COVID-19 Pandemic on People with Parkinson's Disease.

42. Current and projected future economic burden of Parkinson's disease in the U.S.

43. EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson's Disease.

44. Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience.

45. Comparison of an Online-Only Parkinson's Disease Research Cohort to Cohorts Assessed In Person.

46. Electrocardiographic changes predate Parkinson’s disease onset

47. Comparison of an Online-Only Parkinson’s Disease Research Cohort to Cohorts Assessed In Person

48. The NAS-NRC Twin Registry and Duke Twins Study of Memory in Aging: An Update

49. Excessive daytime sleepiness and topographic expansion of Lewy pathology.

50. Longitudinal analyses of cerebrospinal fluid α‐Synuclein in prodromal and early Parkinson's disease